16 September 2026 editorial review · Item
Diabeloop DBLG1: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Diabeloop DBLG1
Scope and findings:
- Read successor rollout primary release; confirms DBLG2 smartphone pathway is distinct from DBLG1 dedicated controller. Narrow current product-generation check; original DBLG1 clinical papers and ongoing supply not fully revalidated.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.
Thriving evidence review — 16 September 2026
Additional ranking review, 16 September 2026. Checked outcome attribution, generation differences, cohort comparability and criterion rationale against primary sources. Corrected false claims and added measured/provisional distinctions. Full findings and source-specific limits are in the AID ranking evidence audit. Numerical ratings were left to the central scoring calibration.